Share Price and Basic Stock Data
Last Updated: December 22, 2025, 11:28 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Cian Healthcare Ltd, a player in the pharmaceuticals sector, has had a mixed trajectory in its revenue generation over the past few years. The company reported sales of ₹68.59 Cr for the year ending March 2023, a noticeable decline from ₹77.87 Cr in the previous fiscal. This downward trend continued into the latest reporting period, with sales standing at ₹61.70 Cr for March 2024. This drop in revenue raises concerns, especially when compared to its earlier growth trajectory of ₹57.09 Cr in March 2020 and ₹73.73 Cr in March 2021. The volatility in sales suggests potential challenges in market positioning or operational efficiency. The operating profit margin (OPM) did exhibit some resilience, peaking at 18.94% in March 2023 but subsequently declining to 16.86% in March 2024. This fluctuation indicates that while the company has managed to control costs to some degree, the sales slowdown is impacting overall profitability. Investors will be keen to see how Cian navigates these challenges in the coming quarters.
Profitability and Efficiency Metrics
Cian Healthcare’s profitability metrics tell a story of both promise and concern. The company recorded a net profit of ₹0.25 Cr for the year ending March 2024, a stark contrast to the ₹2.03 Cr achieved in March 2023. This decline in net profit is accompanied by a fall in earnings per share (EPS), which dropped to ₹0.10 from ₹0.81 in the previous year. While the return on equity (ROE) stands at 30.3%, which is commendable, it is essential to note that the return on capital employed (ROCE) is relatively lower at 10.6%. This discrepancy suggests that while equity holders might be enjoying decent returns, the efficiency of capital utilization could be improved. The cash conversion cycle (CCC) of 235.85 days indicates that the company takes a long time to convert its investments into cash flow. This extended cycle could potentially strain liquidity, making it imperative for Cian to optimize its operational processes to enhance profitability.
Balance Sheet Strength and Financial Ratios
An analysis of Cian Healthcare’s balance sheet reveals a mixed picture of financial health. The company’s market capitalization is ₹13.8 Cr, with borrowings amounting to ₹55 Cr, leading to a total debt-to-equity ratio of 0.96. This figure signifies a moderate level of leverage, which could raise concerns among risk-averse investors. The interest coverage ratio (ICR) is reported at 1.95x, indicating that the company can cover its interest obligations but with limited buffer. Cian’s reserves stood at ₹7 Cr as of March 2024, a significant drop from ₹35 Cr in March 2020, highlighting a potential erosion of financial cushion. The price-to-book value (P/BV) ratio of 0.89x indicates that the stock is trading below its book value, which may attract value investors. However, the declining reserves and high borrowings necessitate a closer examination of the company’s ability to maintain financial stability going forward.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Cian Healthcare has seen a substantial shift, particularly in promoter holdings, which have dwindled from 70.89% in September 2021 to just 27.11% by March 2024. This drastic reduction may raise red flags about insider confidence and could affect overall market sentiment towards the stock. The public’s stake has significantly increased, from 29.11% in September 2021 to 72.89% in March 2024, indicating a growing retail investor base. However, the absence of institutional investors (FIIs and DIIs) could suggest a lack of endorsement from professional fund managers, which often signals caution in the market. With 1,662 shareholders recorded as of March 2024, the growing public interest might be a double-edged sword; while it reflects increasing retail participation, it also poses risks if sentiment shifts negatively.
Outlook, Risks, and Final Insight
Looking ahead, Cian Healthcare faces a mixed bag of opportunities and challenges. The company’s ability to stabilize its revenue and improve profitability metrics will be critical in regaining investor confidence. The declining sales and net profit figures are certainly concerning, as they point to potential underlying issues in market demand or operational efficiency. Additionally, the high levels of debt coupled with decreasing reserves could pose liquidity risks, particularly if operational cash flows do not improve. On the flip side, the attractive P/BV ratio may provide a buying opportunity for value-conscious investors if the company can turn its fortunes around. Nonetheless, the sharp decline in promoter holdings is a significant red flag, suggesting that insiders may not be confident in the company’s near-term prospects. Investors should weigh these factors carefully, considering both the potential for recovery and the risks inherent in Cian’s current financial situation before making investment decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 235/84.3 | 33.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,413 Cr. | 405 | 479/192 | 91.4 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.7 Cr. | 48.2 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.3 Cr. | 33.0 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,312.29 Cr | 1,155.19 | 53.17 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric |
|---|
| Sales |
| Expenses |
| Operating Profit |
| OPM % |
| Other Income |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| Net Profit |
| EPS in Rs |
Last Updated: August 19, 2025, 9:10 pm
Below is a detailed analysis of the quarterly data for Cian Healthcare Ltd based on the most recent figures () and their trends compared to the previous period:
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:58 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Sales | 57 | 74 | 78 | 69 | 62 | 31 |
| Expenses | 50 | 62 | 74 | 56 | 51 | 37 |
| Operating Profit | 7 | 12 | 4 | 13 | 11 | -7 |
| OPM % | 13% | 16% | 6% | 19% | 18% | -21% |
| Other Income | 1 | 0 | 0 | 1 | 0 | -12 |
| Interest | 7 | 8 | 7 | 6 | 6 | 3 |
| Depreciation | 4 | 3 | 4 | 5 | 5 | 4 |
| Profit before tax | -4 | 1 | -6 | 2 | 0 | -26 |
| Tax % | 7% | 91% | -8% | -2% | -1,600% | -0% |
| Net Profit | -4 | 0 | -6 | 2 | 1 | -26 |
| EPS in Rs | -1.62 | 0.02 | -2.21 | 0.81 | 0.34 | -10.39 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2020-2021 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | 133.33% | -50.00% | -2700.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 33.33% | -183.33% | -2650.00% |
Cian Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -6% |
| TTM: | 27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 53% |
| TTM: | -8600% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | -43% |
| 1 Year: | -49% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 2:56 pm
Balance Sheet
Last Updated: December 4, 2025, 2:38 am
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 25 | 25 | 25 | 25 |
| Reserves | 35 | 35 | 30 | 32 | 33 | 7 |
| Borrowings | 73 | 71 | 63 | 61 | 56 | 55 |
| Other Liabilities | 25 | 28 | 47 | 42 | 47 | 69 |
| Total Liabilities | 157 | 157 | 166 | 160 | 161 | 156 |
| Fixed Assets | 39 | 37 | 50 | 45 | 39 | 35 |
| CWIP | 25 | 26 | 13 | 14 | 15 | 15 |
| Investments | 5 | 5 | 5 | 5 | 5 | 5 |
| Other Assets | 87 | 90 | 98 | 97 | 102 | 101 |
| Total Assets | 157 | 157 | 166 | 160 | 161 | 156 |
Below is a detailed analysis of the balance sheet data for Cian Healthcare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 25.00 Cr..
- For Reserves, as of Mar 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2024) to 7.00 Cr., marking a decrease of 26.00 Cr..
- For Borrowings, as of Mar 2025, the value is 55.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 56.00 Cr. (Mar 2024) to 55.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 69.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 47.00 Cr. (Mar 2024) to 69.00 Cr., marking an increase of 22.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 156.00 Cr.. The value appears to be improving (decreasing). It has decreased from 161.00 Cr. (Mar 2024) to 156.00 Cr., marking a decrease of 5.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2024) to 35.00 Cr., marking a decrease of 4.00 Cr..
- For CWIP, as of Mar 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 15.00 Cr..
- For Investments, as of Mar 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 5.00 Cr..
- For Other Assets, as of Mar 2025, the value is 101.00 Cr.. The value appears to be declining and may need further review. It has decreased from 102.00 Cr. (Mar 2024) to 101.00 Cr., marking a decrease of 1.00 Cr..
- For Total Assets, as of Mar 2025, the value is 156.00 Cr.. The value appears to be declining and may need further review. It has decreased from 161.00 Cr. (Mar 2024) to 156.00 Cr., marking a decrease of 5.00 Cr..
However, the Borrowings (55.00 Cr.) are higher than the Reserves (7.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | -66.00 | -59.00 | -59.00 | -48.00 | -45.00 | -62.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Debtor Days | 127.80 | 93.56 | 125.24 | 139.58 | 121.15 |
| Inventory Days | 267.18 | 312.78 | 299.94 | 399.93 | 485.99 |
| Days Payable | 220.03 | 209.37 | 270.46 | 295.80 | 371.29 |
| Cash Conversion Cycle | 174.95 | 196.98 | 154.73 | 243.71 | 235.85 |
| Working Capital Days | 14.77 | 16.14 | 38.30 | 40.66 | 26.27 |
| ROCE % | 6.78% | 0.50% | 6.91% | 5.22% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.10 | 0.81 | -2.32 | 0.02 | -1.62 |
| Diluted EPS (Rs.) | 0.10 | 0.81 | -2.32 | 0.02 | -1.62 |
| Cash EPS (Rs.) | 2.29 | 2.98 | -0.50 | 1.50 | 0.28 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 23.10 | 23.00 | 22.19 | 24.92 | 24.90 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 23.10 | 23.00 | 22.19 | 24.93 | 24.91 |
| Revenue From Operations / Share (Rs.) | 24.68 | 27.44 | 31.15 | 31.56 | 24.44 |
| PBDIT / Share (Rs.) | 4.52 | 5.20 | 1.91 | 5.17 | 3.47 |
| PBIT / Share (Rs.) | 2.34 | 3.03 | 0.20 | 3.69 | 1.57 |
| PBT / Share (Rs.) | 0.01 | 0.79 | -2.37 | 0.38 | -1.48 |
| Net Profit / Share (Rs.) | 0.10 | 0.81 | -2.21 | 0.02 | -1.62 |
| NP After MI And SOA / Share (Rs.) | 0.10 | 0.81 | -2.21 | 0.02 | -1.62 |
| PBDIT Margin (%) | 18.32 | 18.94 | 6.14 | 16.37 | 14.20 |
| PBIT Margin (%) | 9.46 | 11.03 | 0.65 | 11.69 | 6.41 |
| PBT Margin (%) | 0.07 | 2.90 | -7.61 | 1.21 | -6.05 |
| Net Profit Margin (%) | 0.41 | 2.95 | -7.10 | 0.07 | -6.63 |
| NP After MI And SOA Margin (%) | 0.41 | 2.95 | -7.10 | 0.07 | -6.63 |
| Return on Networth / Equity (%) | 0.44 | 3.53 | -9.97 | 0.09 | -6.51 |
| Return on Capital Employeed (%) | 6.14 | 7.94 | 0.53 | 8.66 | 3.39 |
| Return On Assets (%) | 0.15 | 1.26 | -3.33 | 0.03 | -2.41 |
| Long Term Debt / Equity (X) | 0.47 | 0.51 | 0.68 | 0.64 | 0.78 |
| Total Debt / Equity (X) | 0.96 | 1.06 | 1.14 | 1.22 | 1.26 |
| Asset Turnover Ratio (%) | 0.38 | 0.44 | 0.43 | 0.49 | 0.00 |
| Current Ratio (X) | 1.09 | 1.14 | 1.14 | 1.10 | 1.12 |
| Quick Ratio (X) | 0.46 | 0.57 | 0.56 | 0.56 | 0.71 |
| Inventory Turnover Ratio (X) | 1.59 | 0.96 | 1.24 | 1.54 | 0.00 |
| Interest Coverage Ratio (X) | 1.95 | 2.28 | 0.74 | 1.56 | 1.14 |
| Interest Coverage Ratio (Post Tax) (X) | 1.04 | 1.34 | 0.15 | 1.03 | 0.47 |
| Enterprise Value (Cr.) | 106.16 | 129.47 | 109.32 | 94.69 | 104.74 |
| EV / Net Operating Revenue (X) | 1.72 | 1.89 | 1.40 | 1.28 | 1.83 |
| EV / EBITDA (X) | 9.39 | 9.96 | 22.84 | 7.84 | 12.91 |
| MarketCap / Net Operating Revenue (X) | 0.83 | 1.02 | 0.61 | 0.35 | 0.61 |
| Price / BV (X) | 0.89 | 1.22 | 0.85 | 0.45 | 0.60 |
| Price / Net Operating Revenue (X) | 0.83 | 1.02 | 0.61 | 0.35 | 0.61 |
| EarningsYield | 0.00 | 0.02 | -0.11 | 0.00 | -0.10 |
After reviewing the key financial ratios for Cian Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 0.10. This value is below the healthy minimum of 5. It has decreased from 0.81 (Mar 23) to 0.10, marking a decrease of 0.71.
- For Diluted EPS (Rs.), as of Mar 24, the value is 0.10. This value is below the healthy minimum of 5. It has decreased from 0.81 (Mar 23) to 0.10, marking a decrease of 0.71.
- For Cash EPS (Rs.), as of Mar 24, the value is 2.29. This value is below the healthy minimum of 3. It has decreased from 2.98 (Mar 23) to 2.29, marking a decrease of 0.69.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 23.10. It has increased from 23.00 (Mar 23) to 23.10, marking an increase of 0.10.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 23.10. It has increased from 23.00 (Mar 23) to 23.10, marking an increase of 0.10.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 24.68. It has decreased from 27.44 (Mar 23) to 24.68, marking a decrease of 2.76.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 4.52. This value is within the healthy range. It has decreased from 5.20 (Mar 23) to 4.52, marking a decrease of 0.68.
- For PBIT / Share (Rs.), as of Mar 24, the value is 2.34. This value is within the healthy range. It has decreased from 3.03 (Mar 23) to 2.34, marking a decrease of 0.69.
- For PBT / Share (Rs.), as of Mar 24, the value is 0.01. This value is within the healthy range. It has decreased from 0.79 (Mar 23) to 0.01, marking a decrease of 0.78.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 0.10. This value is below the healthy minimum of 2. It has decreased from 0.81 (Mar 23) to 0.10, marking a decrease of 0.71.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 0.10. This value is below the healthy minimum of 2. It has decreased from 0.81 (Mar 23) to 0.10, marking a decrease of 0.71.
- For PBDIT Margin (%), as of Mar 24, the value is 18.32. This value is within the healthy range. It has decreased from 18.94 (Mar 23) to 18.32, marking a decrease of 0.62.
- For PBIT Margin (%), as of Mar 24, the value is 9.46. This value is below the healthy minimum of 10. It has decreased from 11.03 (Mar 23) to 9.46, marking a decrease of 1.57.
- For PBT Margin (%), as of Mar 24, the value is 0.07. This value is below the healthy minimum of 10. It has decreased from 2.90 (Mar 23) to 0.07, marking a decrease of 2.83.
- For Net Profit Margin (%), as of Mar 24, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 2.95 (Mar 23) to 0.41, marking a decrease of 2.54.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 0.41. This value is below the healthy minimum of 8. It has decreased from 2.95 (Mar 23) to 0.41, marking a decrease of 2.54.
- For Return on Networth / Equity (%), as of Mar 24, the value is 0.44. This value is below the healthy minimum of 15. It has decreased from 3.53 (Mar 23) to 0.44, marking a decrease of 3.09.
- For Return on Capital Employeed (%), as of Mar 24, the value is 6.14. This value is below the healthy minimum of 10. It has decreased from 7.94 (Mar 23) to 6.14, marking a decrease of 1.80.
- For Return On Assets (%), as of Mar 24, the value is 0.15. This value is below the healthy minimum of 5. It has decreased from 1.26 (Mar 23) to 0.15, marking a decrease of 1.11.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.47. This value is within the healthy range. It has decreased from 0.51 (Mar 23) to 0.47, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.96. This value is within the healthy range. It has decreased from 1.06 (Mar 23) to 0.96, marking a decrease of 0.10.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.38. It has decreased from 0.44 (Mar 23) to 0.38, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 24, the value is 1.09. This value is below the healthy minimum of 1.5. It has decreased from 1.14 (Mar 23) to 1.09, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 24, the value is 0.46. This value is below the healthy minimum of 1. It has decreased from 0.57 (Mar 23) to 0.46, marking a decrease of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.59. This value is below the healthy minimum of 4. It has increased from 0.96 (Mar 23) to 1.59, marking an increase of 0.63.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 1.95. This value is below the healthy minimum of 3. It has decreased from 2.28 (Mar 23) to 1.95, marking a decrease of 0.33.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 1.04. This value is below the healthy minimum of 3. It has decreased from 1.34 (Mar 23) to 1.04, marking a decrease of 0.30.
- For Enterprise Value (Cr.), as of Mar 24, the value is 106.16. It has decreased from 129.47 (Mar 23) to 106.16, marking a decrease of 23.31.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.72. This value is within the healthy range. It has decreased from 1.89 (Mar 23) to 1.72, marking a decrease of 0.17.
- For EV / EBITDA (X), as of Mar 24, the value is 9.39. This value is within the healthy range. It has decreased from 9.96 (Mar 23) to 9.39, marking a decrease of 0.57.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 23) to 0.83, marking a decrease of 0.19.
- For Price / BV (X), as of Mar 24, the value is 0.89. This value is below the healthy minimum of 1. It has decreased from 1.22 (Mar 23) to 0.89, marking a decrease of 0.33.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 23) to 0.83, marking a decrease of 0.19.
- For EarningsYield, as of Mar 24, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 23) to 0.00, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Cian Healthcare Ltd:
- Net Profit Margin: 0.41%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.14% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.44% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.04
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 53.17)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.96
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.41%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Milkat No. 3339, Block No.1, From South Side, Pune Maharashtra 412308 | cs@cian.co https://www.cian.co |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Suraj Shriniwas Zanwar | Managing Director |
| Mrs. Swati Maheshwari | Independent Director |
| Mr. Paresh Arun Shah | Non Executive Director |
| Mr. Sunil Saini | Independent Director |
FAQ
What is the intrinsic value of Cian Healthcare Ltd?
Cian Healthcare Ltd's intrinsic value (as of 22 December 2025) is 48.21 which is 883.88% higher the current market price of 4.90, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 12.2 Cr. market cap, FY2025-2026 high/low of 7.66/2.97, reserves of ₹7 Cr, and liabilities of 156 Cr.
What is the Market Cap of Cian Healthcare Ltd?
The Market Cap of Cian Healthcare Ltd is 12.2 Cr..
What is the current Stock Price of Cian Healthcare Ltd as on 22 December 2025?
The current stock price of Cian Healthcare Ltd as on 22 December 2025 is 4.90.
What is the High / Low of Cian Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Cian Healthcare Ltd stocks is 7.66/2.97.
What is the Stock P/E of Cian Healthcare Ltd?
The Stock P/E of Cian Healthcare Ltd is .
What is the Book Value of Cian Healthcare Ltd?
The Book Value of Cian Healthcare Ltd is 13.0.
What is the Dividend Yield of Cian Healthcare Ltd?
The Dividend Yield of Cian Healthcare Ltd is 0.00 %.
What is the ROCE of Cian Healthcare Ltd?
The ROCE of Cian Healthcare Ltd is 10.6 %.
What is the ROE of Cian Healthcare Ltd?
The ROE of Cian Healthcare Ltd is 30.3 %.
What is the Face Value of Cian Healthcare Ltd?
The Face Value of Cian Healthcare Ltd is 10.0.